Open AccessClinical case of lupus erythematosus panniculitis
Author(s) -
Nataliа P. Teplyuk,
Н П Теплюк,
O. V. Grabovskaya,
О В Грабовская,
Polina A. Razhev,
Ражева Полина Александровна
Publication year - 2020
Publication title -
rossijskij žurnal kožnyh i veneričeskih boleznej
Language(s) - English
Resource type - Journals
eISSN - 2412-9097
pISSN - 1560-9588
DOI - 10.17816/dv60811
Subject(s) - medicine , panniculitis , hydroxychloroquine , dermatology , prednisolone , systemic lupus erythematosus , lupus erythematosus , etiology , connective tissue disease , population , disease , systemic disease , immunology , pathology , autoimmune disease , covid-19 , infectious disease (medical specialty) , antibody , environmental health
BACKGROUND: This clinical case is interesting because of extreme rarity of lupus panniculitis in the population, as well as the possible risk of developing systemic lupus erythematosus.
CASE REPORT: The article presents a clinical observation of a rare skin disorder lupus erythematosus panniculitis and the results of a successful combined treatment of the disease with systemic glucocorticoids (prednisolone), and an antimalarial agent (hydroxychloroquine). A review of the literature on the etiology, pathogenesis, and diagnosis of lupus panniculitis has been conducted.
CONCLUSION. Early detection of lupus erythematosus panniculitis (LEP) makes systemic steroid therapy and quinoline drugs more effective in achieving remission. That is why dynamic monitoring of patients with LEP is important to identify new or progressive symptoms.